SOPHAGUSCAPANKREASCAMAGENCA GASTROINTESTINALTUMOURS C18.0 C18.2 C18.3 C18.4 C18.5 C18.6 C18.7 C18.8 C18.9 C19 C20
Conditions
Interventions
Group 1: Gastrointestinal cancer patients under systematic therapy with (spectral)-CT scans for clinical indications and additional MRI exams, clinical muscle and functional tests, and questionnaires
Sponsors
University Medical Center Hamburg-EppendorfDepartment of Diagnostic and Interventional Radiology and Nuclear Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Patients with gastrointestinal cancer entities under palliative or adjuvant chemotherapy 2) Clinical indication for a CT scan 3) CT scan in the spectral-CT
Exclusion criteria
Exclusion criteria: 1) Presence of other independent risk factors for sarcopenia (e.g. neuromuscular diseases, severe dysphagia, malabsorption due to extensive previous abdominal operations, known food intolerances). 2) Surgery with immobilization during the study period 3) MRI contraindications (e.g. foreign materials (pacemaker, staple sutures), claustrophobia) 4) Spondylodesis material at the level of the 3rd lumbar vertebra
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Endpoint: - Agreement and variance between spectral-CT and MRI liver and muscle fat values | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: - Relationship of spectral CT liver and muscle fat values ??to single energy CT values - Relationship of spectral CT liver and muscle fat values ??to clinical sarcopenia parameters - Predictive value of spectral CT liver and muscle fat values ??for the clinical outcome | — |
Countries
Germany
Contacts
Public ContactAlina Busch
Universitätsklinikum Hamburg - Eppendorf
Outcome results
None listed